Catalog shorthand and the biological hormone name have different meanings on this page. A protocol that requires endogenous GLP-2 would not be satisfied by tirzepatide. Record the exact analyte and expected molecular identity when ordering and receiving the material. The distinction prevents an error that a name only catalog search could miss.
Representative product imagery. Verify the physical label and lot documentation on receipt.
Metabolic Research
GLP-2
In stock·Ships in 1–2 business days
GLP-2 (Tirzepatide) research material supplied with batch-level documentation. Each unit is labeled with a traceable lot code and links to its corresponding analytical report.
Select size7 options
Select pack sizeSave 18% on kits
1 × 5 mg$37.99
In stockSelected size 5 mgSC-GLP2-005
Transparent volume pricing10-vial peptide kits save 18%.
Secure checkout US & EU dispatch
Research use only acknowledgment required at checkout
Report not published
Compound context
What researchers study
GLP-2 is the catalog label used here for tirzepatide research material. Tirzepatide acts at GIP and GLP-1 receptors in published research. It is not the endogenous intestinal hormone glucagon like peptide-2. Preserve the full molecule name in a laboratory record so the catalog shorthand does not create a receptor or identity error.
The discovery literature connects the development code LY3298176 with tirzepatide and describes its dual receptor activity. Later work examines differences between signaling pathways and receptor responses. Those findings are more specific than calling it a double strength GLP compound. The number in a catalog nickname does not describe clinical potency or a universal receptor hierarchy.
A dual agonist does not necessarily generate equal responses at both receptors under every condition. Receptor expression and the selected measurement influence the comparison. A study that measures one second messenger may not describe receptor trafficking or another pathway. Define the readout before interpreting a result as evidence about the material's broader behavior.
Scope limitCheck the tirzepatide identity and chemical form against the current lot report. Research material is not an approved pharmaceutical product. We don't provide human dosing, treatment substitution or personal combination schedules.
Serenity Compounds is not a compounding pharmacy or chemical compounding facility as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act.
Common laboratory focus
Activity at two receptor types must be demonstrated with methods suited to each target. Different maximal responses or apparent potencies can occur across assays. A common concentration scale helps organize a comparison, but equal nominal mass isn't enough to establish equal exposure. Reference ligands and matched controls are necessary for interpretation.
Tirzepatide peptide for sale in a research catalog is a different product category from a prescribed formulation. Clinical trials involve specified manufacturing and administration conditions. Their results do not certify a research vial or create a personal protocol. Review the analytical documentation for its actual laboratory purpose rather than borrowing a medicine's claims.
Quality documentation
Know what your laboratory receives.
Batch records are published for transparency and should be independently reviewed by qualified research personnel.
Current certificateGLP-2 · Report not publishedSee original reportView report
- Tamper-evident packaging
- Lot and SKU traceability
- Independent analytical review
Continue exploring
